{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:18:15Z","timestamp":1790878695963,"version":"4.1.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Gestational diabetes mellitus (GDM) is a widespread pregnancy complication, affecting approximately 7% to 10% of pregnancies worldwide and presenting risks for both maternal and fetal health. Traditional treatments, including lifestyle changes, insulin, and oral hypoglycemic agents, have limitations, particularly in terms of safety and potential fetal impacts. Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for type 2 diabetes, have shown promise in managing GDM by improving glycemic control, enhancing insulin sensitivity, and assisting in weight management. However, safety and efficacy data in pregnancy remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review analyzed 8 clinical trials from ClinicalTrials.gov examining the use of GLP-1 liraglutide, semaglutide, and exenatide in GDM treatment. Studies varied in design, with the majority employing randomized, interventional protocols focusing on glycemic control and insulin sensitivity. Key outcome measures included hemoglobin A1c levels, glucose tolerance, insulin secretion, and progression to type 2 diabetes postpartum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>GLP-1 receptor agonists effectively manage blood glucose and reduce pregnancy complications associated with GDM. However, side effects such as gastrointestinal discomfort and mild hypoglycemia were common, and all GLP-1 are categorized as pregnancy Category C by the U.S. Food and Drug Administration (FDA), with potential implications for fetal health due to transplacental passage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This review highlights the need for large-scale, long-term studies to establish standardized protocols and assess the safety and efficacy of GLP-1 in managing GDM, potentially expanding therapeutic options for this condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044917","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:07:02Z","timestamp":1759781222000},"page":"e44917","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-0128","authenticated-orcid":false,"given":"Fahad S.","family":"Alshehri","sequence":"first","affiliation":[{"name":"Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1172\/JCI200524531","article-title":"Gestational diabetes mellitus.","volume":"115","author":"Buchanan","year":"2005","journal-title":"J Clin Invest"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-019-0098-8","article-title":"Gestational diabetes mellitus.","volume":"5","author":"McIntyre","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"15804","DOI":"10.3390\/ijerph192315804","article-title":"Evolution of gestational diabetes mellitus across continents in 21st century.","volume":"19","author":"Dluski","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.286.20.2516","article-title":"Gestational diabetes mellitus.","volume":"286","author":"Jovanovic","year":"2001","journal-title":"JAMA"},{"key":"R5-20260526","doi-asserted-by":"crossref","first-page":"399","DOI":"10.15537\/smj.2015.4.10307","article-title":"Gestational diabetes mellitus.","volume":"36","author":"Alfadhli","year":"2015","journal-title":"Saudi Med J"},{"key":"R6-20260526","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1507\/endocrj.EJ19-0367","article-title":"Risk factors during the early postpartum period for type 2 diabetes mellitus in women with gestational diabetes.","volume":"67","author":"Kawasaki","year":"2020","journal-title":"Endocr J"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/GRF.0000000000000585","article-title":"Risk factors for progression from gestational diabetes to postpartum type 2 diabetes: a review.","volume":"64","author":"Bengtson","year":"2021","journal-title":"Clin Obstet Gynecol"},{"key":"R8-20260526","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s00125-016-3985-5","article-title":"Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark.","volume":"59","author":"Damm","year":"2016","journal-title":"Diabetologia"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4093\/dmj.2022.0348","article-title":"Gestational diabetes mellitus and its implications across the life span.","volume":"47","author":"Wicklow","year":"2023","journal-title":"Diabetes Metab J"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.3390\/nu12103050","article-title":"Diet and healthy lifestyle in the management of gestational diabetes mellitus.","volume":"12","author":"Rasmussen","year":"2020","journal-title":"Nutrients"},{"key":"R11-20260526","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1479-828X.2011.01329.x","article-title":"Gestational diabetes mellitus: who requires insulin therapy?","volume":"51","author":"Wong","year":"2011","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R12-20260526","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.semperi.2014.08.012","article-title":"Gestational diabetes mellitus management with oral hypoglycemic agents.","volume":"38","author":"Ryu","year":"2014","journal-title":"Seminars in Perinatology"},{"key":"R13-20260526","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40200-015-0169-7","article-title":"Gestational diabetes mellitus: challenges in diagnosis and management.","volume":"14","author":"Mpondo","year":"2015","journal-title":"J Diabetes Metab Disord"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s10995-017-2261-8","article-title":"\u201cIt\u2019s a very big burden on me\u201d: women\u2019s experiences using insulin for gestational diabetes.","volume":"21","author":"Figueroa Gray","year":"2017","journal-title":"Matern Child Health J"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2230-8210.149317","article-title":"Metformin in gestational diabetes: an emerging contender.","volume":"19","author":"Singh","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"R17-20260526","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1055\/s-2004-826175","article-title":"Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.","volume":"36","author":"Nauck","year":"2004","journal-title":"Horm Metab Res"},{"issue":"2_suppl","key":"R18-20260526","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/1474651408100523","article-title":"Pharmacology of GLP-1-based therapies.","volume":"8","author":"Holst","year":"2008","journal-title":"Br J Diabetes Vasc Dis"},{"issue":"2 Suppl 1","key":"R19-20260526","first-page":"eS10","article-title":"Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.","volume":"111","author":"Spellman","year":"2011","journal-title":"J Am Osteopath Assoc"},{"key":"R20-20260526","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"R22-20260526","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/dom.12082","article-title":"Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus.","volume":"15","author":"Bonde","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R23-20260526","doi-asserted-by":"crossref","first-page":"9072492","DOI":"10.1155\/2020\/9072492","article-title":"Serum glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in association with the risk of gestational diabetes: a prospective case-control study.","volume":"2020","author":"Mosavat","year":"2020","journal-title":"J Diabetes Res"},{"key":"R24-20260526","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1152\/ajpendo.00361.2023","article-title":"Maternal GLP-1 receptor activation inhibits fetal growth.","volume":"326","author":"Qiao","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R25-20260526","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1042\/CS20220890","article-title":"Maternal glucagon-like peptide-1 is positively associated with fetal growth in pregnancies complicated with obesity.","volume":"137","author":"Dumolt","year":"2023","journal-title":"Clin Sci (Lond)"},{"key":"R26-20260526","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy.","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"key":"R27-20260526","doi-asserted-by":"crossref","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology information services.","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"R28-20260526","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(24)00825-0","article-title":"Epidemiology and management of gestational diabetes.","volume":"404","author":"Sweeting","year":"2024","journal-title":"Lancet"},{"key":"R29-20260526","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1515\/jpm-2024-0121","article-title":"Ultrasound prediction of fetal macrosomia in pregnancies complicated by diabetes mellitus: a systematic review and meta-analysis.","volume":"52","author":"Panunzi","year":"2024","journal-title":"J Perinat Med"},{"key":"R30-20260526","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1038\/s41598-024-56790-z","article-title":"Gestational diabetes mellitus, hypertension, and dyslipidemia as the risk factors of preeclampsia.","volume":"14","author":"Aziz","year":"2024","journal-title":"Sci Rep"},{"key":"R31-20260526","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/jdi.14220","article-title":"Postpartum life interventions to prevent type 2 diabetes in women with gestational diabetes: a systematic review and meta-analysis.","volume":"15","author":"Wang","year":"2024","journal-title":"J Diabetes Investig"},{"key":"R32-20260526","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s43856-024-00491-1","article-title":"Effective interventions in preventing gestational diabetes mellitus: a systematic review and meta-analysis.","volume":"4","author":"Takele","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"R33-20260526","first-page":"CD012037","article-title":"Insulin for the treatment of women with gestational diabetes.","volume":"11","author":"Brown","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R34-20260526","first-page":"62","article-title":"Gestational diabetes and oral hypoglycemic agents: a fresh look at the safety profile.","volume":"15","author":"Langer","year":"2003","journal-title":"OBG Manage"},{"key":"R35-20260526","doi-asserted-by":"crossref","first-page":"e175634","DOI":"10.1172\/JCI175634","article-title":"The GLP-1 journey: from discovery science to therapeutic impact.","volume":"134","author":"Drucker","year":"2024","journal-title":"J Clin Invest"},{"key":"R36-20260526","first-page":"e51151","article-title":"Novel therapies in diabetes: a comprehensive narrative review of GLP-1 receptor agonists, SGLT2 inhibitors, and beyond.","volume":"15","author":"Olanrewaju","year":"2023","journal-title":"Cureus"},{"key":"R37-20260526","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12325-022-02394-w","article-title":"GLP-1 agonists for weight loss: pharmacology and clinical implications.","volume":"40","author":"Moore","year":"2023","journal-title":"Adv Ther"},{"key":"R38-20260526","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/jcph.2487","article-title":"Pharmacotherapy of weight-loss and obesity with a focus on GLP 1-receptor agonists.","volume":"64","author":"Myerson","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"R39-20260526","first-page":"53","article-title":"Clinical impact of liraglutide as a treatment of obesity.","volume":"13","author":"Alruwaili","year":"2021","journal-title":"Clin Pharmacol"},{"key":"R40-20260526","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/jpm12030424","article-title":"Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes.","volume":"12","author":"Kyriakidou","year":"2022","journal-title":"J Pers Med"},{"key":"R41-20260526","doi-asserted-by":"crossref","first-page":"645617","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation.","volume":"12","author":"Meier","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R42-20260526","doi-asserted-by":"crossref","first-page":"107520","DOI":"10.1016\/j.jdiacomp.2019.107520","article-title":"Oral semaglutide in type 2 diabetes.","volume":"34","author":"Anderson","year":"2020","journal-title":"J Diabetes Complications"},{"key":"R43-20260526","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/dom.14568","article-title":"Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.","volume":"24","author":"Johansen","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R44-20260526","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13318-020-00665-x","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple escalating doses of PEGylated exenatide (PB-119) in healthy volunteers.","volume":"46","author":"Cui","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R45-20260526","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14740338.2015.987122","article-title":"Potential side effects to GLP-1 agonists: understanding their safety and tolerability.","volume":"14","author":"Consoli","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R46-20260526","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials.","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R47-20260526","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists.","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"R48-20260526","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R49-20260526","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"R50-20260526","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/0118715303252109231023115112","article-title":"Case series: exposure to glucagon-like peptide-1 receptor agonist in the first trimester of pregnancy in two siblings.","volume":"24","author":"Dogan","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R51-20260526","doi-asserted-by":"crossref","first-page":"106984","DOI":"10.1016\/j.ntt.2021.106984","article-title":"Long-term functional alterations following prenatal GLP-1R activation.","volume":"87","author":"Graham","year":"2021","journal-title":"Neurotoxicol Teratol"},{"key":"R52-20260526","doi-asserted-by":"crossref","first-page":"110977","DOI":"10.1016\/j.mce.2020.110977","article-title":"Protein restriction during pregnancy impairs intra-islet GLP-1 and the expansion of beta-cell mass.","volume":"518","author":"Pereira de Arruda","year":"2020","journal-title":"Mol Cell Endocrinol"},{"key":"R53-20260526","doi-asserted-by":"crossref","first-page":"170481","DOI":"10.1016\/j.peptides.2020.170481","article-title":"The glucagon-like peptide-1 (GLP-1) analog exenatide ameliorates intrauterine adhesions in mice.","volume":"137","author":"Ma","year":"2021","journal-title":"Peptides"},{"key":"R54-20260526","doi-asserted-by":"crossref","first-page":"1215356","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R55-20260526","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1191\/0960327103ht402oa","article-title":"Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4).","volume":"22","author":"Hiles","year":"2003","journal-title":"Hum Exp Toxicol"},{"key":"R57-20260526","doi-asserted-by":"crossref","first-page":"e23258","DOI":"10.1002\/jbt.23258","article-title":"GLP-1 rescued gestational diabetes mellitus-induced suppression of fetal thalamus development.","volume":"37","author":"You","year":"2023","journal-title":"J Biochem Mol Toxicol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:28:59Z","timestamp":1779805739000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":56,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044917","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"2024-12-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}